METAGENOMI THERAPEUTICS INC (MGX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:MGX • US59102M1045

1.54 USD
0 (0%)
Last: Feb 3, 2026, 02:14 PM
Fundamental Rating

3

Taking everything into account, MGX scores 3 out of 10 in our fundamental rating. MGX was compared to 524 industry peers in the Biotechnology industry. MGX has a great financial health rating, but its profitability evaluates not so good. MGX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year MGX has reported negative net income.
  • In the past year MGX has reported a negative cash flow from operations.
MGX Yearly Net Income VS EBIT VS OCF VS FCFMGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • MGX has a Return On Assets of -35.79%. This is in the better half of the industry: MGX outperforms 61.83% of its industry peers.
  • MGX has a Return On Equity of -49.73%. This is in the better half of the industry: MGX outperforms 66.41% of its industry peers.
Industry RankSector Rank
ROA -35.79%
ROE -49.73%
ROIC N/A
ROA(3y)-17.76%
ROA(5y)N/A
ROE(3y)-27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGX Yearly ROA, ROE, ROICMGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • MGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGX Yearly Profit, Operating, Gross MarginsMGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

  • MGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MGX has less shares outstanding than it did 1 year ago.
  • MGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MGX Yearly Shares OutstandingMGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
MGX Yearly Total Debt VS Total AssetsMGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • MGX has an Altman-Z score of -1.46. This is a bad value and indicates that MGX is not financially healthy and even has some risk of bankruptcy.
  • MGX has a Altman-Z score of -1.46. This is comparable to the rest of the industry: MGX outperforms 54.20% of its industry peers.
  • MGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.46
ROIC/WACCN/A
WACC8.9%
MGX Yearly LT Debt VS Equity VS FCFMGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 6.42 indicates that MGX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.42, MGX is doing good in the industry, outperforming 65.46% of the companies in the same industry.
  • A Quick Ratio of 6.42 indicates that MGX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 6.42, MGX is in the better half of the industry, outperforming 66.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.42
Quick Ratio 6.42
MGX Yearly Current Assets VS Current LiabilitesMGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.15% over the past year.
  • The Revenue for MGX has decreased by -43.88% in the past year. This is quite bad
  • Measured over the past years, MGX shows a very strong growth in Revenue. The Revenue has been growing by 499.26% on average per year.
EPS 1Y (TTM)4.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.84%
Revenue 1Y (TTM)-43.88%
Revenue growth 3Y499.26%
Revenue growth 5YN/A
Sales Q2Q%-24.8%

3.2 Future

  • Based on estimates for the next years, MGX will show a small growth in Earnings Per Share. The EPS will grow by 7.87% on average per year.
  • MGX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -28.04% yearly.
EPS Next Y9.05%
EPS Next 2Y13.95%
EPS Next 3Y11.39%
EPS Next 5Y7.87%
Revenue Next Year-46.01%
Revenue Next 2Y-34.84%
Revenue Next 3Y-22.7%
Revenue Next 5Y-28.04%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MGX Yearly Revenue VS EstimatesMGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
MGX Yearly EPS VS EstimatesMGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MGX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGX Price Earnings VS Forward Price EarningsMGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGX Per share dataMGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.95%
EPS Next 3Y11.39%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for MGX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

METAGENOMI THERAPEUTICS INC

NASDAQ:MGX (2/3/2026, 2:14:52 PM)

1.54

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)03-11
Inst Owners17.78%
Inst Owner Change-6.4%
Ins Owners9.75%
Ins Owner Change4.4%
Market Cap57.80M
Revenue(TTM)30.91M
Net Income(TTM)-88.74M
Analysts80
Price Target9.52 (518.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.33%
Min EPS beat(2)6.75%
Max EPS beat(2)13.9%
EPS beat(4)3
Avg EPS beat(4)5.25%
Min EPS beat(4)-16.48%
Max EPS beat(4)16.83%
EPS beat(8)6
Avg EPS beat(8)16.91%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)12.52%
Min Revenue beat(2)9.18%
Max Revenue beat(2)15.86%
Revenue beat(4)3
Avg Revenue beat(4)-3.61%
Min Revenue beat(4)-48.67%
Max Revenue beat(4)15.86%
Revenue beat(8)7
Avg Revenue beat(8)20.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.43%
EPS NY rev (1m)0%
EPS NY rev (3m)1.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.87
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-2.4
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0.82
BVpS4.75
TBVpS4.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.79%
ROE -49.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.76%
ROA(5y)N/A
ROE(3y)-27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.02%
Cap/Sales 2.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.42
Quick Ratio 6.42
Altman-Z -1.46
F-Score2
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)365.8%
Cap/Depr(5y)N/A
Cap/Sales(3y)36.38%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.84%
EPS Next Y9.05%
EPS Next 2Y13.95%
EPS Next 3Y11.39%
EPS Next 5Y7.87%
Revenue 1Y (TTM)-43.88%
Revenue growth 3Y499.26%
Revenue growth 5YN/A
Sales Q2Q%-24.8%
Revenue Next Year-46.01%
Revenue Next 2Y-34.84%
Revenue Next 3Y-22.7%
Revenue Next 5Y-28.04%
EBIT growth 1Y-4.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.41%
EBIT Next 3Y-14.71%
EBIT Next 5YN/A
FCF growth 1Y-10.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.32%
OCF growth 3YN/A
OCF growth 5YN/A

METAGENOMI THERAPEUTICS INC / MGX FAQ

Can you provide the ChartMill fundamental rating for METAGENOMI THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MGX.


What is the valuation status of METAGENOMI THERAPEUTICS INC (MGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to METAGENOMI THERAPEUTICS INC (MGX). This can be considered as Overvalued.


What is the profitability of MGX stock?

METAGENOMI THERAPEUTICS INC (MGX) has a profitability rating of 1 / 10.


Can you provide the financial health for MGX stock?

The financial health rating of METAGENOMI THERAPEUTICS INC (MGX) is 7 / 10.